GlassScriptPhysician profile
Steven L Roby
NPI 1801152434
$1,074.03
in general payments reported to CMS, 2019-2025
23 companies · $83.25 in 2025
The $83.25 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $105 · 2022: $24.52 · 2023: $44.57 · 2024: $76.21 · 2025: $83.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $161.90 | 2019-2025 | Ozempic |
| Amgen INC. | $125.74 | 2019-2025 | Prolia, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.46 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $76.32 | 2019-2020 | |
| Lilly USA, LLC | $68.84 | 2019-2025 | Jardiance, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $62.43 | 2023-2024 | Trelegy Ellipta |
| Abbott Laboratories | $42.77 | 2022-2024 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $39.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $38.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.47 | 2020 | |
| Horizon Therapeutics Plc | $25.38 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $24.80 | 2019-2020 | |
| Pfizer INC. | $24.05 | 2019 | |
| Abiomed | $19.17 | 2025 | |
| Shire North American Group INC | $14.17 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.55 | 2019 | |
| Amarin Pharma, INC. | $11.85 | 2019 | |
| Abbvie INC. | $11.34 | 2019 | |
| Endogastric Solutions, INC | $10.24 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Roby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.